Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

• DOI: 10.1111/dom.13172
• Publication Date: 2017-11-27T10:19:03Z
• Authors: Tina Vilsbøll; Stephen C. Bain; Lawrence A. Leiter; Ildiko Lingvay; David Matthews; Rafael Simó; Ida Carøe Helmark; Nelun Wijayasinghe; Michael Larsen
• Keywords: Semaglutide; Glycated haemoglobin

To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial programme.The programme evaluated efficacy and safety of semaglutide, a glucagon-like peptide-1 analogue, for treatment type 2 diabetes (T2D). In 6, 2-year, pre-approval cardiovascular outcomes trial, semaglutide was associated with significant increase in risk DR complications (DRC) vs placebo. trials were evaluated, post hoc analyses 6 conducted. These included subgroup to identify at-risk patients mediation analysis initial change glycated haemoglobin (HbA1c; percentage-points at week 16) as covariate, examine role magnitude reduction HbA1c an intermediate factor affecting DRC.There no imbalance adverse events 1 5 Japanese trials. The majority effect placebo may be attributed rapidity during first 16 weeks who had pre-existing poor glycaemic control baseline, treated insulin.Early worsening is known phenomenon improvement insulin; DRC findings are consistent this. Guidance regarding early recommended insulin. Similar recommendations appropriate semaglutide.